Relationship between L-arginine/asymmetric dimethylarginine, homocysteine, folic acid, vitamin B levels, and coronary artery ectasia

Coronary Artery Disease

Volumn 21, Issue 8, 2010, Pages 445-449

  Koc, Fatih ^a   Ardic, Idris ^b   Erdem, Sami ^c   Kalay, Nihat ^b   Ozbek, Kerem ^a   Yarlioglues, Mikail ^b   Ceyhan, Koksal ^a   Celik, Atac ^a   Kadi, Hasan ^a   Taner, Alpaslan ^c   Sahin, Semsettin ^a   Onalan, Orhan ^a   Kaya, Mehmet Gungor ^b  

^a GAZIOSMANPASA UNIVERSITY   (Turkey)

^b ERCIYES UNIVERSITY   (Turkey)

^c SELCUK UNIVERSITY   (Turkey)

Author keywords

asymmetric dimethylarginine; coronary artery ectasia; endothelial dysfunction; folic acid; homocysteine; L arginine; vitamin B12; vitamin B6

Indexed keywords

ARGININE; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; N(G),N(G) DIMETHYLARGININE; PYRIDOXINE;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY DISEASE; CORONARY ARTERY ECTASIA; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; FEMALE; FOLIC ACID BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; VITAMIN BLOOD LEVEL;

AGED; ARGININE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY VESSELS; DILATATION, PATHOLOGIC; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TURKEY; VITAMIN B COMPLEX;

EID: 78649518914     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCA.0b013e32833fd22b     Document Type: Article

References (45)

1. Hartnell GG, Parnell BM, Pridie RB. Coronary artery ectasia, its prevalence and clinical significance in 4993 patients. Br Heart J 1985; 54:392-395.
2. Manginas A, Cokkinos DV. Coronary artery ectasias: Imaging, functional assessment and clinical implications. Eur Heart J 2006; 27:1026-1031.
3. Sharma SN, Kaul U, Sharma S, Wasiv HS, Manchanda SC, Bahl VK, et al. Coronary arteriographic profile in young and old Indian patients with ischaemic heart disease: A comparative study. Indian Heart J 1990; 42:365-369.
4. Walker HA, McGing E, Fisher I, Böger RH, Bode-Böger SM, Jackson G, et al. Endothelium-dependent vasodilation is independent of the plasma Larginine/ ADMA ratio in men with stable angina: Lack of effect of oral Larginine on endothelial function, oxidative stress and exercise performance. J Am Coll Cardiol 2001; 38:499-505.
5. Vallance P, Leone A, Calver A, Collier J, Moncada S. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol 1992; 20 (Suppl 12):S60-S62.
6. Mittermayer F, Namiranian K, Pleiner J, Schaller G, Wolzt M. Acute Escherichia coli endotoxaemia decreases the plasma L-arginine/ asymmetrical dimethylarginine ratio in humans. Clin Sci 2004; 106:577-581.
7. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339:572-575.
8. Abbasi F, Asagmi T, Cooke JP, Lamendola C, McLaughlin T, Reaven GM, et al. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 2001; 88:1201-1203.
9. Usui M, Matsuoka H, Miyazaki H, Ueda S, Okuda S, Imaizumi T. Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci 1998; 62:2425-2430.
10. Pettersson A, Hedner T, Milsom I. Increased circulating concentrations of asymmetric dimethyl arginine (ADMA), an endogenous inhibitor of nitric oxide synthesis, in preeclampsia. Acta Obstet Gynecol Scand 1998; 77:808-813.
11. Böger RH, Bode-Böger SM, Thiele W, Junker W, Alexander K, Frölich J. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 1997; 95:2068-2074.
12. Böger RH, Bode-Böger SM, Sydow K, Heistad DD, Lentz SR. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst( e)inemia or hypercholesterolemia. Arterioscler Thromb Vasc Biol 2000; 20:1557-1564.
13. Pancharuniti N, Lewis CA, Sauberlich HE, Perkins LL, Go RCP, Alvarez JO, et al. Plasma homocyst(e)ine, folate, and vitamin B12 concentrations and risk for early-onset coronary artery disease. Am J Clin Nutr 1994; 59:940-948.
14. Robinson K, Mayer EL, Miller D, Green R, Van Lente F, Gupta A, et al. Hyperhomocysteinemia and low pyridoxal phosphate: Common and independent reversible risk factors for coronary artery disease. Circulation 1995; 92:2825-2830.
15. Stampfer MJ, Malinow MR,Willett WC, Newcomer LM, Upson B, Ullmann D, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992; 268:877-881.
16. Robinson K, Arheart K, Refsum H, Brattström L, Boers G, Ueland P, et al., European COMAC Group. Low circulating folate and vitamin B6 concentrations: Risk factors for stroke, peripheral vascular disease, and coronary artery disease. Circulation 1998; 97:437-443.
17. Bode-Böger SM, Böger RH, Kienke S, Junker W, Frölich JC. Elevated L-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits. Biochem Biophys Res Commun 1996; 219:598-603.
18. Böger RH, Bode-Böger SM, Phivthong-ngam L, Böhme M, Brandes RP, Mügge A, et al. Dietary L-arginine slows the progression of atherosclerosis in cholesterol-fed rabbits: Comparison with lovastatin. Circulation 1997; 96:1282-1290.
19. Swaye PS, Fisher LD, Litwin P, Vignola PA, Judkins MP, Kemp HG, et al. Aneurysmal coronary artery disease. Circulation 1983; 67:134-138.
20. Chen BM, Xia LW, Zhao RQ. Determination of N(G),N(G)-dimethylarginine in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1997; 692:467-471.
21. Kosar F, Sincer I, Aksoy Y, Ozerol I. Elevated plasma homocysteine levels in patients with isolated coronary artery ectasia. Coron Artery Dis 2006; 17:23-27.
22. Hurst T, Olson TH, Olson LE, Appleton CP. Cardiac syndrome X and endothelial dysfunction: New concepts in prognosis and treatment. Am J Med 2006; 119:560-566.
23. Akyü rek O, Berkalp B, Sayin T, Kumbasar D, Kervancioǧlu C, Oral D. Altered coronary flow properties in diffuse coronary artery ectasia. Am Heart J 2003; 145:66-72.
24. Okyay K, Cengel A, Sahinarslan A, Tavil Y, Turkoglu S, Biberoglu G, et al. Plasma asymmetric dimethylarginine and L-arginine levels in patients with cardiac syndrome X. Coron Artery Dis 2007; 18:539-544.
25. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327:524-526. (Pubitemid 17085822)
26. Böger RH, Bode-Böger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, et al. Asymmetric dimethylarginine (ADMA): A novel risk factor for endothelial dysfunction: Its role in hypercholesterolemia. Circulation 1998; 98:1842-1847.
27. Böger RH, Sydow K, Borlak J, Thum T, Lenzen H, Schubert B, et al. LDL cholesterol upregulates synthesis of asymmetric dimethylarginine in human endothelial cells. Involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res 2000; 87:99-105.
28. Perticone F, Sciacqua A, Maio R, Perticone M, Maas R, Boger RH, et al. Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension. J Am Coll Cardiol 2005; 46:518-523.
29. Cay S, Cagirci G, Akcay M, Karakurt O, Kahraman E, Yazihan N, et al. Asymmetric dimethylarginine levels in patients with coronary artery ectasia. Kardiol Pol 2009; 67:1362-1368.
30. Yoo JH, Lee SC. Elevated levels of plasma homocyst(e)ine and asymmetric dimethylarginine in elderly patients with stroke. Atherosclerosis 2001; 158:425-430.
31. Boger RH, Lentz SR, Bode-Boger SM, Knapp HR, Haynes WG. Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. Clin Sci Lond 2001; 100:161-167.
32. Sahinarslan A, Cengel A, Biberoglu G, Hasanoglu A, Turkoglu S, Timurkaynak T. Plasma asymmetric dimethylarginine level and extent of lesion at coronary angiography. Coron Artery Dis 2006; 17:605-609.
33. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: Probable benefits of increasing folic acid intake. JAMA 1995; 274:1049-1057.
34. Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, et al. Plasma homocysteine as a risk factor for vascular disease: The european concerted action project. JAMA 1997; 277:1775-1778.
35. Christensen B, Refsum H, Vintermyr O, Ueland PM. Homocysteine export from cells cultured in the presence of physiological or superfluous levels of methionine: Methionine loading of nontransformed, transformed, proliferating and quiescent cells in culture. J Cell Biol 1991; 146:52-62.
36. Upchurch GR Jr, Welch GN, Fabian AJ, Freedman JE, Johnson JL, Keaney JF, et al. Homocysteine decrease bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 1997; 272:17012-17017.
37. Harker LA, Ross R, Slichter SJ, Scott CR. Homocysteine-induced arteriosclerosis: The role of endothelial cell injury and platelet response in its genesis. J Clin Invest 1976; 58:731-741.
38. Wall RT, Harlan JM, Harker LA, Striker GE. Homocysteine-induced endothelial cell injury in vitro: A model for the study of vascular injury. Thromb Res 1980; 18:113-121.
39. Song Y, Cook NR, Albert CM, Van Denburgh M, Manson JE. Effect of homocysteine-lowering treatment with folic acid and B vitamins on risk of type 2 diabetes in women: A randomized, controlled trial. Diabetes 2009; 58:1921-1928.
40. Armitage JM, Bowman L, Clarke RJ, Wallendszus K, Bulbulia R, Rahimi K, et al. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group. Effects of homocysteinelowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: A randomized trial. JAMA 2010; 303:2486-2494.
41. Rimm EB, Willett WC, Hu FB, Sampson L, Colditz GA, Manson JE, et al. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA 1998; 279:359-364. (Pubitemid 28133864)
42. Hodis HN, Mack WJ, Dustin L, Mahrer PR, Azen SP, Detrano R, et al. High-dose B vitamin supplementation and progression of subclinical atherosclerosis: A randomized controlled trial. Stroke 2009; 40:730-736.
43. Ebbing M, Bleie O, Ueland PM, Nordrehaug JE, Nilsen DW, Vollset SE, et al. Mortality and cardiovascular events in patients treated with homocysteinelowering B vitamins after coronary angiography: A randomized controlled trial. JAMA 2008; 300:795-804.
44. Løland KH, Bleie O, Blix AJ, Strand E, Ueland PM, Refsum H, et al. Effect of homocysteine-lowering B vitamin treatment on angiographic progression of coronary artery disease: A Western Norway B Vitamin Intervention Trial (WENBIT) substudy. Am J Cardiol 2010; 105:1577-1584.
45. Turhan H, Erbay AR, Yasar AS, Bicer A, Sahin O, Basar N, et al. Plasma homocysteine levels in patients with isolated coronary artery ectasia. Int J Cardiol 2005; 104:158-162. (Pubitemid 41316984)